Trials / Completed
CompletedNCT00360269
Atomoxetine Treatment for ADHD and Marijuana Dependence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to determine if atomoxetine treatment combined with motivational enhancement therapy is effective in reducing marijuana use in adult individuals with attention-deficit hyperactivity disorder and marijuana dependence.
Detailed description
The purpose of this study is to determine whether the medication atomoxetine, or Strattera, plus 3 sessions of counseling can help people to reduce the symptoms of ADHD and to help cut back on their marijuana use. Participation in the study is approximately 12 weeks of medication treatment and doctor's visits once a week. The first 2 visits consist of evaluations to determine if you qualify to participate. These visits are approximately 2-3 hours long and will include questions about your past and present substance use, psychiatric history, a routine physical exam, bloodwork, and paper and pencil questionnaires about your marijuana use. Once you are enrolled in the study, visits are typically 30 minutes long, once a week. The one-on-one counseling sessions regarding marijuana use are 1 hour long and you will have 3 sessions throughout the study. If you qualify for this study, you will receive either atomoxetine, or a placebo (sugar pill). Study participants will have a 50% chance of receiving atomoxetine. Atomoxetine is a non-stimulant, commonly used to treat ADHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atomoxetine | 25 to 100 mg daily |
| PROCEDURE | Motivational enhancement therapy | Three sessions |
| DRUG | Placebo | 25 to 100 mg daily |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-08-04
- Last updated
- 2014-12-30
- Results posted
- 2012-04-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00360269. Inclusion in this directory is not an endorsement.